Catherine Cortez Masto

It is extremely helpful to our Committee as we contribute ideas for moderating health care costs while actually improving the quality of patient satisfaction and outcomes

I appreciate the hearing today. Thank you all for being here.

It is just another way of defending dignity and involving, again, the caregiver and that whole team

We have spent a number of hearings... trying to address and understand how those patients and their families dealing with Alzheimer's and dementia navigate the health care system.

This is exactly why it was so important that the CFPB required more data collection and more oversight over lending activities.

Despite the loss of public HMDA data, each of your agencies still has a requirement to ensure that Latinos, African Americans, women and other people are not rejected for loans due to their gender or ethnicity.

I was the Attorney General of Nevada during the financial crisis and saw first-hand how big banks targeted vulnerable people and communities of color.

I have a team that focuses just on grant writing, literally to provide assistance to organizations.

I think it is time now to stop talking about it and put systems in place where we can start accurately collecting this data.

I am really interested in how we, at the Federal level, can help streamline some of these.

I just have to echo Senator Heitkamp's words.

I am all about oversight, accountability, tracking it, and making sure there is no fraud.

I think we all agree with that.

It is critical that we work together to improve the lives of Native youth.

We should collect more and better data but we should also listen to what the tribes are saying.

We believe that a default opt-in is the right approach, that this is the best way to empower consumers and increase their confidence, and we think that that's really good for business.

I think for that reason, what we are trying to do here and why we haven't been able to do it yet is it's a very difficult thing to try to put one kind of template over this idea of privacy.

I do support an opt-in for personal identifiable information that is sensitive and where we draw that line is the question and it could be struck in any number of places.

I echo all of the questions that have been asked.

Is there anything that you are hearing today from the private sector and the national labs that you think needs to be addressed?

Thank you, Madam Chair, and thank you for this hearing today.

I think we have to look at this in a holistic approach.

They should get some credit for that.

That level playing field of regulation does not mean that we roll back regulation, does it?

OK. And let me finally--data collection.